The “European Lupus Meetings” is a major forum for all people interested in the disease: with approximately 800 physicians of various disciplines (internal medicine, rheumatology, nephrology, dermatology, obstetrics and gynecology, neurology), health professionals, regulatory agencies, pharmaceutical industry and patient representatives.

ImmuPharma recently had confirmation from Dr. Sylviane Muller, Research Director at CNRS, Strasbourg, France and the key inventor of Lupuzor, that she has been invited to present at the conference.  Her talk is planned  in the Basic and Translational Symposium (15-16.30pm CET) on Thursday April 24.  The title of the session is called “A novel way of immunomodulation in lupus”.  Her presentation will focus partly on the on the highly competitive and efficacious mode of mechanism of Lupuzor^TM, ImmuPharma’s potential blockbuster drug for Lupus, a chronic autoimmune disease. Lupuzor^TM has received Special Protocol Assessment and Fast Track Designation from the FDA for a Phase III trial.

Also in attendance at the conference will be two of ImmuPharma’s eminent ‘Scientific Advisory Board’, Dr. Daniel J. Wallace, Associate Director, Rheumatology Fellowship Program, Cedars-Sinai Medical Center, Los Angeles, and a leading practitioner within the field of Lupus, and Prof. Cees GM Kallenberg, M.D., Ph.D. Prof. Department of Rheumatology and Clinical Immunology, University Medical Center Groningen who is a member of  the ‘European Organisation Committee’ for this forthcoming Lupus meeting. (Full biographies can be found in ‘Notes to Editors’).

Details of the presentation given by Dr. Slyvianne Muller will be provided by ImmuPharma following the conference.